Home／Products & Technology／Nuclear Medicine Applications
Scope of Nuclear Medicine Imaging
Diagnostic Imaging
Letting the Body Speak: Precision Lesion Visualization
By introducing radiopharmaceuticals into the body, human tissues emit "endogenous radiation." Highly sensitive detection equipment captures these radiation signals to accurately map lesion distribution based on tissue uptake and attenuation properties, providing cellular-level insights beyond the reach of conventional anatomical imaging.
Targeted Radionuclide Therapy
Micro-Scale Precision: Targeted Eradication of Cancer Cells
Once target sites are identified, therapeutic radiopharmaceuticals deliver micro-scale energy directly into tumors. High-energy particles released during radioactive decay (α or β particles) focus precisely on diseased tissue, generating potent ionization effects that shatter cancer cell DNA while minimizing collateral damage to surrounding healthy tissue.
Precision Medicine / Theranostics Theranostics
See What You Treat, Treat What You See
Theranostics utilizes diagnostic imaging to stratify eligible patients, followed by targeted radionuclide therapy using matching molecular ligands. This approach not only enhances therapeutic efficacy but also significantly reduces the systemic side effects of conventional treatments, ushering in a new era of precision oncology—a core focus of Petpharmbio's strategic R&D roadmap.
▲ Therapeutic Radiopharmaceuticals Fall into Two Primary Classes:
α-Emitting Radionuclides — Emit alpha particles with high linear energy transfer (LET) but an extremely short path length (<100 μm, cell-diameter scale), ideal for treating micro-metastases. Representative Isopes: 225Ac, 211At
β-Emitting Radionuclides — Emit beta particles with longer tissue penetration range and lower LET compared to alpha particles, suited for local tumor control. Representative Isotopes: 177Lu, 161Tb
⚡ Therapeutic Radiopharmaceutical R&D
β Decay (Beta Decay)
Moderate energy with millimeter-range tissue penetration (0.5 MeV / ~1 mm), providing effective localized tumor control.
Key Radionuclides: 177Lu, 131I
α Decay (Alpha Decay)
High cytotoxicity with cellular-scale range (<100 μm), delivering maximal localized cell killing with minimal off-target exposure.
Key Radionuclides: 225Ac, 211At
Targeted therapeutic radiopharmaceuticals represent the core focus of Petpharmbio's ongoing research and development initiatives.